GIBF partners with selected companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders.
Based in the Greater Bay Area of South China, GIBF offers international companies the resources and expertise to create value in their JVs through multiple channels, such as expanding and expediting their global clinical trials, early entry into the Chinese market, IPO in Hong Kong under the new Biotech18-A chapter introduced by the SEHK or similar channels in Chinese stock exchanges, and local M&A and licensing deals.
